Other · developed by UroGen Pharma
UGN-201 is a drug administered intravesically (directly into the bladder) and studied in non-muscle invasive bladder cancer, including carcinoma in situ and recurrent urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05375903 | Phase 1 | Non-muscle Invasive Bladder Cancer | Completed | URGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder CancerCarcinoma in Situ of BladderNMIBCNon-muscle Invasive Bladder CancerUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent
Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.
See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
URGN catalysts and pipeline →